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Lung cancer is one of the leading causes of cancer
death in Taiwan1,2 and worldwide,3 with minimal
improvement in its poor survival.4 In addition to
research into innovative treatment modalities, it is
important for patients to receive the best standard
of care so as to achieve the optimal outcome.
However, the ideal scenario that every patient
has received optimal treatment does not always
come to pass in real clinical practice. Significant
variation in the pattern of care (POC) is often
observed, and a wide range of adherence to quality
measures, from 19% to 100%, has been reported,
depending on where the patient lives.5 For lung
cancer, 41–69% of patients with non-small cell
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Background/Purpose: To investigate the quality of care (QOC) for lung cancer in Taiwan, as measured by
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of tissue diagnosis, diagnostic computed tomography (CT), and CT or magnetic resonance imaging for staging
advanced non-small cell lung cancer was noted in the four participating hospitals from 2002 to 2004.
Conclusion: It is very likely that significant variation in QOC for lung cancer in Taiwan exists among 
different types but not locations of hospitals, at least in the diagnostic domain. The introduction of internal
benchmarking (TCDB and core measures) was associated with some changes, at least in some diagnostic
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ORIGINAL ARTICLE
lung cancer (NSCLC, the major histologic type)
actually received the recommended therapy in a US
population-based study.6 Similar findings have
been reported for some aspects of POC in Asia.7
The US National Cancer Institute (NCI) has pro-
posed to improve the quality of cancer care by
developing core process and outcome measures.8
In a US annual report based on cancer registries
and NCI POC studies, Edwards et al9 reported 
a decline in cancer mortality as the dissemination
of guideline-based treatment increased. They also
found that cancer registries are an important source
for monitoring quality of care (QOC). In Taiwan,
after approval of the Cancer Prevention and Man-
agement Law in 2003, a project was initiated by
the Bureau of Health Promotion, Department 
of Health, and a revised cancer registry (Taiwan
Cancer Database; TCDB) was initiated in 2003.10
In the present study, we investigated the present
QOC for lung cancer in Taiwan and the impact of
the TCDB, represented by variation in POC,11 as
revealed by the recent TCDB core measure report.12
Methods
Patients and hospitals
According to the recent TCDB core measure 
report,12 the analyzed patients and hospitals were
those that participated in the TCDB project as
initiated by the Bureau of Health Promotion,
Department of Health. Initially, four hospitals
participated in the TCDB for lung cancer in 2002.
The number of participating hospitals increased
to 27 in 2004, which included all medical cen-
ters in Taiwan at the present time.13 Hospital
characteristics (Table 1) were specified, including
location, service volume, level (medical center 
or regional hospital), and ownership (public or
private). The geographic location was divided into
northern (from Kee-Lung city to Hsin-Chu county)
and non-northern regions to ensure adequate hos-
pital numbers within each category. The number
of participating hospitals within north, middle,
south and east Taiwan was 10, five, 10 and two,
respectively. The hospital volume was based on an-
nual operation number. The cut-off point (n = 34)
was based on a recent endemic study.14 Hospital
level was divided into medical centers and regional
hospitals, as evaluated by the Taiwan Department
of Health.13 This study was based on the data 
reported from these 27 participating hospitals
from year 2002 (n = 4) to 2003 (n = 5) and 2004
(n = 27), excluding one big public medical center
in north Taiwan as an outlier for its exceptional
reported data.
QOC and core measures
QOC evaluation was based on core measure data
in association with the TCDB project. The prelim-
inary core measure items were determined by the
Delphi method, as previously reported.15 In view
of the feasibility of data retraction, 16 core mea-
sures (6 in the diagnostic and 10 in the therapeutic
domain) were finalized, as listed in Table 2. For
index D1, either cytologic or pathologic exami-
nation was considered to be compliant with the
core measure. For index D3, either cardiac func-
tion or pulmonary testing was considered to be
compliant with the core measure. For index D4,
execution of at least one systematic work-up (bone
scan, computed tomography [CT], magnetic res-
onance imaging [MRI], positron emission tomog-
raphy) was considered to be compliant. For indexes
T2 and T7, the numerator was based on National
Health Insurance (NHI) claim records (code 67010
or 67011). For index T8, the denominator was
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Table 1. Characteristics of participating hospitals (n = 27)




Service volume Large* Small
8 19




*Annual operation number ≥ 34.
based on TCDB hospital records. In addition to the
above indexes for which multiple core measures
were reported, for other indexes, the numerators
and denominators were based on the only one
reported core measure in the recent TCDB core
measure report.12 As revealed in this report, the
measurement was based on TCDB, cancer registry,
and claims data from NHI. The POC for each
core measure was calculated by summation of the
numerator divided by summation of the denom-
inator among different hospital characteristics.
Statistical analysis
POC was expressed as the ratio of patients who
received the suggested action among those who
were eligible. Patients who had visited different
hospitals were counted separately in hospital-
specific indexes. Differences between groups were
tested by the χ2 or Fisher’s exact test. Time trend
was tested by the χ2 test for trends. For example
(see index D2 in Table 3), among 3055 NSCLC
patients reported by the 10 hospitals located in
northern Taiwan in 2004, 1825 (59.7%) received
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Table 2. Selected core measures
Indexes Notation Numerator Denominator
D1 Tissue diagnosis Those with cytopathologic Coded as lung cancer in registry
diagnostic approach
D2 Chest CT Those with chest CT at Coded as NSCLC in registry
diagnosis
D3 Preoperative cardiopulmonary Those with preoperative cardiac Coded as NSCLC receiving operation
evaluation or pulmonary evaluation
D4 Preoperative staging Those with staging work-up Coded as NSCLC stage 1–3a 
receiving operation
D5 Staging in advanced stage: Those with bone scan at Coded as NSCLC stage 3b–4
bone scan diagnosis
D6 Staging in advanced stage: Those with brain or spine Coded as NSCLC stage 3b–4
brain or spine MRI MRI at diagnosis
T1 Radical operation for early Those receiving radical Coded as NSCLC stage 1–2 
stage NSCLC operation receiving operation
T2 Conservative operation for Those receiving conservative Coded as NSCLC stage 1–2 
early stage NSCLC operation receiving operation
T3 Lymph node dissection or sampling Those receiving lymph node Coded as NSCLC stage 1–2 
for early stage NSCLC dissection or sampling receiving operation
T4 Adjuvant RT for early NSCLC with Those also receiving RT Coded as NSCLC stage 1–2 receiving
positive margin operation with positive margin
T5 Chemotherapy or RT for Those also receiving RT or Coded as NSCLC stage 1–2 
non-operated early NSCLC chemotherapy without operation
T6 Radical operation for stage 3a Those receiving radical Coded as NSCLC stage 3a receiving 
NSCLC operation operation
T7 Conservative operation for Those receiving conservative Coded as NSCLC stage 3a receiving
stage 3a NSCLC operation receiving operation
T8 Lymph node dissection or sampling Those receiving lymph node Coded as NSCLC stage 3a receiving 
for stage 3a NSCLC dissection or sampling operation
T9 Adjuvant RT for stage 3a NSCLC Those also receiving RT Coded as NSCLC stage 3a receiving
with positive margin operation with positive margin
T10 Chemotherapy or RT for Those also receiving RT or Coded as NSCLC stage 3a without 
non-operated stage 3a NSCLC chemotherapy operation
CT = computed tomography; NSCLC = non-small-cell lung cancer; MRI = magnetic resonance imaging; RT = radiotherapy.
the recommended CT examination. The corre-
sponding figures were 58.1% (1850/3185) for
those 17 hospitals in non-northern Taiwan. The
difference was not significantly different (χ2 test,
p = 0.18). Analyses were conducted using SAS
version 9.0 (SAS Institute, Cary, NC, USA) and
Egret version 2 (Cytel, Cambridge, MA, USA).
Results
In 2004, 6624 cases of lung cancer were reported
by 26 participating hospitals (excluding the one
outlier), which may account for 90% of new lung
cancer cases in Taiwan, assuming similar lung
cancer incidence in 2003 and 2004. There were
7415 cases of lung cancer in Taiwan in 2003, and
the data for 2004 are not yet available.1
Variation in POC according to 
hospital location
Among most (12/16) of the indexes, there was no
significant variation in POC among northern
and non-northern hospitals (Table 3). However,
northern hospitals were associated with more
preoperative imaging staging work-up (index D4),
radical operation for early stage NSCLC (T1),
lymph node sampling or dissection for early stage
NSCLC (T3), and conservative surgery for stage
3a NSCLC (T6).
Variation in POC according to hospital
service volume
Significant variation in POC existed between
large- and small-volume hospitals, mainly in the
diagnostic domain (5/6) rather than the thera-
peutic domain (1/10) (Table 4). Large-volume hos-
pitals were associated with more tissue diagnosis
(D1), CT (D2) and staging work-up for advanced
stage NSCLC (D5 and D6), less preoperative 
imaging staging (D4), and similar preoperative
cardiopulmonary evaluation (D3).
Variation in POC according to hospital level
(medical center or regional hospital)
Significant variation in POC existed between
medical centers and regional hospitals, mainly
in the diagnostic domain (5/6) rather than the
therapeutic domain (1/10) (Table 5). Medical cen-
ters were associated with more tissue diagnosis
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Events Total % Events Total %
D1 2137 3444 0.620 2195 3580 0.613 0.53
D2 1825 3055 0.597 1850 3185 0.581 0.18
D3 400 451 0.887 371 422 0.879 0.72
D4 285 345 0.826 240 326 0.736 0.005†
D5 1127 2226 0.506 1105 2297 0.481 0.09
D6 1359 2226 0.611 1422 2297 0.619 0.55
T1 195 267 0.730 120 259 0.463 < 0.001†
T2 41 267 0.154 49 259 0.189 0.28
T3 262 267 0.981 240 259 0.927 0.003†
T4 4 14 0.286 3 14 0.214 1
T5 32 85 0.376 47 115 0.409 0.65
T6 52 78 0.667 33 67 0.493 0.034†
T7 7 78 0.090 12 67 0.179 0.11
T8 55 56 0.982 38 41 0.927 0.31
T9 4 7 0.571 3 4 0.750 1
T10 65 115 0.565 93 153 0.608 0.48
*Indexes D1–6 and T1–10: see text; †p < 0.05.
(D1), CT (D2) and staging work-up for advanced
stage NSCLC (D5 and D6), less preoperative 
imaging staging (D4), and similar preoperative
cardiopulmonary evaluation (D3).
Variation in POC according to hospital
ownership (public or private)
Significant variation in POC existed between public
and private hospitals, all in the diagnostic domain
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Table 4. Pattern of care variation among large- and small-volume hospitals
Indexes*
Large volume† Small volume†
p
Events Total % Events Total %
D1 2886 4378 0.659 1446 2646 0.546 < 0.001‡
D2 2488 3888 0.640 1187 2352 0.505 < 0.001‡
D3 586 662 0.885 185 211 0.877 0.74
D4 393 516 0.762 132 155 0.852 0.02‡
D5 1521 2833 0.537 711 1690 0.421 < 0.001‡
D6 1872 2833 0.661 909 1690 0.538 < 0.001‡
T1 233 399 0.584 82 127 0.646 0.22
T2 79 399 0.198 11 127 0.087 0.004‡
T3 377 399 0.945 125 127 0.984 0.06
T4 3 15 0.200 4 13 0.308 0.67
T5 44 109 0.404 35 91 0.385 0.78
T6 70 117 0.598 15 28 0.536 0.55
T7 17 117 0.145 2 28 0.071 0.53
T8 77 81 0.951 16 16 1.000 1
T9 3 6 0.500 4 5 0.800 0.55
T10 92 149 0.617 66 119 0.555 0.3
*Indexes D1–6 and T1–10: see text; †cut-off for large and small volume is annual operation ≥ 34 or not; ‡p < 0.05.
Table 5. Pattern of care variation between medical centers and regional hospitals
Indexes*
Medical centers Regional hospitals
p
Events Total % Events Total %
D1 3793 5801 0.654 539 1223 0.441 < 0.001†
D2 3175 5152 0.616 500 1088 0.460 < 0.001†
D3 695 790 0.880 76 83 0.916 0.33
D4 472 612 0.771 53 59 0.898 0.02†
D5 1942 3752 0.518 290 771 0.376 < 0.001†
D6 2387 3752 0.636 394 771 0.511 < 0.001†
T1 289 477 0.606 26 49 0.531 0.31
T2 84 477 0.176 6 49 0.122 0.34
T3 454 477 0.952 48 49 0.980 0.71
T4 7 26 0.269 0 2 0.000 1
T5 57 159 0.358 22 41 0.537 0.04†
T6 80 135 0.593 5 10 0.500 0.74
T7 17 135 0.126 2 10 0.200 0.62
T8 88 92 0.957 5 5 1.000 1
T9 7 11 0.636 0 0 NA NA
T10 134 228 0.588 24 40 0.600 0.88
*Indexes D1–6 and T1–10: see text; †p < 0.05. NA = not applicable.
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Events Total % Events Total %
D1 1788 2454 0.729 2544 4570 0.557 < 0.001†
D2 1642 2166 0.758 2033 4074 0.499 < 0.001†
D3 391 436 0.897 380 437 0.870 0.21
D4 293 350 0.837 232 321 0.723 < 0.001†
D5 914 1486 0.615 1318 3037 0.434 < 0.001†
D6 1153 1486 0.776 1628 3037 0.536 < 0.001†
T1 167 276 0.605 148 250 0.592 0.76
T2 59 276 0.214 31 250 0.124 0.006
T3 261 276 0.946 241 250 0.964 0.31
T4 2 8 0.250 5 20 0.250 1
T5 29 68 0.426 50 132 0.379 0.51
T6 45 74 0.608 40 71 0.563 0.59
T7 11 74 0.149 8 71 0.113 0.52
T8 47 50 0.940 46 47 0.979 0.62
T9 3 6 0.500 4 5 0.800 0.55
T10 52 82 0.634 106 186 0.570 0.33
*Indexes D1–6 and T1–10: see text; †p < 0.05.
(5/6) (Table 6). Public hospitals were associated
with more tissue diagnosis (D1), CT (D2) and stag-
ing work-up for advanced stage NSCLC (D5 and
D6), preoperative imaging staging (D4), and simi-
lar preoperative cardiopulmonary evaluation (D3).
Variation in POC according to composite
hospital types
Because all five public hospitals included in the
analysis were also large-volume medical centers,
hospitals were further divided into four types
(public or private large medical centers, private
small medical centers, and private regional hos-
pitals) for further comparison of heterogeneity.
Significant variations in POC were noted mainly
in the diagnostic domain (5/6) rather than the
therapeutic domain (1/10) (Table 7). For tissue
diagnosis (D1), CT (D2) and staging work-up for
advanced stage NSCLC (D5 and D6), the de-
scending order was public hospitals, followed by
small medical centers, large medical centers and
regional hospitals. For preoperative imaging stag-
ing (D4), the order was regional hospitals, public
hospitals, small private medical centers and large
private medical centers.
Impact of core measures on the four
participants since 2002
Temporal variations in POC for the four partici-
pants since 2002 are listed in Table 8. Most (13/16)
of the indexes were stable during this period.
However, increased utilization of some indexes
in the diagnostic domain was noted, which in-
cluded tissue diagnosis (D1), CT (D2) and staging
work-up for advanced stage NSCLC (D6).
Discussion
To the best of our knowledge, this is the first study
on QOC for lung cancer in Taiwan based on core
measures and cancer registry. We found that there
were significant variations in the diagnostic do-
main between different types of hospital, but less
marked differences between hospital locations.
There was also some significant increase in utiliza-
tion of some diagnostic domains after introduction
of the TCDB. One of the reasons is that staging
information was not available in the prior cancer
registry, which hindered the availability of registry-
based QOC studies.
Quality of care for lung cancer in Taiwan
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Table 7. Pattern of care variation between different kinds of hospitals
Indexes* Public
Private large Private small 
Private regional p
medical center medical center
D1 0.729 0.571 0.637 0.441 < 0.001†
D2 0.758 0.491 0.544 0.460 < 0.001†
D3 0.897 0.863 0.852 0.916 0.29
D4 0.837 0.602 0.823 0.898 < 0.001†
D5 0.615 0.451 0.458 0.376 < 0.001†
D6 0.776 0.534 0.560 0.511 < 0.001†
T1 0.605 0.537 0.718 0.531 0.06
T2 0.214 0.163 0.064 0.122 0.01†
T3 0.946 0.943 0.987 0.980 0.32
T4 0.250 0.143 0.364 0.000 0.62
T5 0.426 0.366 0.260 0.537 0.054
T6 0.608 0.581 0.556 0.500 0.91
T7 0.149 0.140 0.000 0.200 0.34
T8 0.940 0.968 1.000 1.000 0.76
T9 0.500 NA 0.800 NA NA
T10 0.634 0.597 0.532 0.600 0.62
*Indexes D1–6 and T1–10: see text; †p < 0.05.
Table 8. Temporal variations in pattern of care among four participants from 2002 to 2004
Indexes* 2002 2003 2004 p
D1 0.72 0.72 0.76 0.008†
D2 0.71 0.75 0.76 0.002†
D3 0.92 0.84 0.92 0.89
D4 0.86 0.88 0.91 0.11
D5 0.66 0.69 0.68 0.34
D6 0.72 0.75 0.78 0.003†
T1 0.55 0.44 0.54 0.81
T2 0.24 0.15 0.27 0.51
T3 0.94 0.94 0.97 0.23
T4 0.47 0.5 0.25 0.56
T5 0.45 0.48 0.45 0.99
T6 0.47 0.47 0.61 0.18
T7 0.14 0.16 0.23 0.26
T8 1.00 0.97 0.9 0.07
T9 0.09 0.33 0.5 0.09
T10 0.69 0.67 0.69 0.98
*Indexes D1–6 and T1–10: see text; †p < 0.05, χ2 test for trend.
However, there are still some shortcomings with
the present TCDB and core measures, which are
also limitations of the present study. Firstly, small-
cell lung cancer was not included in the majority
of core measures, although it constitutes only a
small proportion (9% in 2003) of all cases of lung
cancer.1 Secondly, in the therapeutic domain, there
is a lack of core measures for locally advanced
and advanced NSCLC (73% of NSCLC in TCDB
2004),12 which is because of a lack of performance
status in the present TCDB. Thirdly, the core mea-
sures reported so far are all process measures with-
out core outcome measures, which are planned
for evaluation in TCDB,10 but they are not avail-
able for the short follow-up period (5 participating
hospitals before 2004). Fourthly, the dimensions
of the present core measures were limited, mostly
focusing on effectiveness instead of other dimen-
sions such as patient-centeredness or timeliness,
not to mention other cancer-specific dimensions
suggested by the recent American Society of
Clinical Oncology (ASCO) and European Society
for Medical Oncology (ESMO) consensus state-
ment.16 However, most of these limitations were
caused by difficulty in measurement.
Most of the significant variations we found fell
in the diagnostic rather than the therapeutic do-
main, which may partly be because surgery was
infrequently used for lung cancer (16% in cancer
registry 2003).1 Among the 16 core measures used
by the present TCDB report, significant varia-
tions in the diagnostic domain were noted among
hospital types (volume, accreditation level and
ownership), which was consistent with a previous
systematic review.17 On the other hand, although
geographic variation has been reported in many
studies (such as in the recent National Initiative for
Cancer Care Quality report),5 the geographic vari-
ations (northern vs. non-northern) in the present
study were not significant in most (12/16) of these
indexes.
We found that POC in Taiwan was consistent
with new clinical evidence in a previous study
based on registry data from a single institution.18
We also found increasing compliance with some
core measures with increasing years with the
TCDB project. A previous systematic review has
revealed that outcome is improved with the adop-
tion of clinical practice guidelines.19 As these
core measures were established from evidence-
based clinical guidelines,15 we believe that QOC
for lung cancer in Taiwan will be improved in the
near future.
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